Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 64.85 -0.49 (-0.75%)
price chart
Bristol-Myers to buy Amylin for about $5.3 billion
NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.
Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B  FierceBiotech
Bristol-Myers in Deal for Amylin Valued at $7 Billion  New York Times (blog)
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Teva Spikes Higher as Chairman Purchases One Million Shares
In January, Jeremy Levin from Bristol-Myers Squibb (NYSE: BMY) was named CEO of the company. Morgan Stanley (NYSE: MS) maintains research coverage of the company at an Equal-Weight rating with a price target of $44. Citigroup (NYSE: C) maintains ...
Terminally ill patients should have access to last-chance therapies
But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and development of its medicines.
Bristol-Myers Immune Drug Puts Deadly Cancers on Hold in Study
June 4 (Bloomberg) -- The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
How to Profit From Bristol-Myers Squibb's New Cancer Drugs
Bristol-Myers Squibb announced this week that not one but two of its experimental immunotherapy drugs, not chemotherapy drugs, immunotherapy, have shown amazing results in advanced stages of several types of cancer, and the results are long lasting.
Bristol-Myers authorizes $3 billion share buyback
Drugmaker Bristol-Myers Squibb Co (BMY.N) on Tuesday said its board authorized the repurchase of $3 billion of the company's common stock in addition to the $3 billion share buyback program it announced in 2010.
FDA Once Again Delays Approval Of Apixaban (Eliquis)  Forbes
FDA Unexpectedly Delays Move on Anticlotting Drug  New York Times
Bristol, AstraZeneca among Amylin bidders-sources
LONDON/BOSTON AstraZeneca Plc (AZN.L) and Bristol-Myers Squibb Co (BMY.N) are among several pharmaceutical giants that have submitted initial bids for Amylin Pharmaceuticals Inc AMLN.